title: Mycoplasma pneumoniae infection in hospitalized adult patients with community-acquired pneumonia in China.
abstract: BACKGROUND
  This study aimed to investigate the prevalence, clinical and radiographic features, and antibiotic responses of Mycoplasma pneumoniae (M. pneumoniae) infections in hospitalized adults with community-acquired pneumonia (CAP) in China.
  
  
  METHODS
  Serum specimens collected from 189 CAP patients in both acute phase and convalescence were tested for IgG, IgA, and IgM mixed antibodies specific to M. pneumoniae. The clinical and radiographic characteristics and efficacy of three antibiotic regimens were compared between patients with M. pneumoniae infection and those without.
  
  
  RESULTS
  Among 189 CAP patients, 88 (46.6%) were positive for M. pneumoniae infection. Compared to the negative patients, patients with M. pneumoniae infection were significantly younger, had higher rates of dry cough, and had white blood cell counts of <1010/L, but had less purulent sputum. Radiography further showed more centrilobular nodules, ground-glass opacities, tree-in-bud patterns and thickened bronchovascular bundles, but less pleural effusion and larger tracts of real opacities in patients with M. pneumoniae infections. Among the three regimens used, patients with moxifloxacin required significantly shorter fever abatement, treatment, and hospitalization times than those with azithromycin plus ceftriaxone and ceftriaxone only.
  
  
  CONCLUSIONS
  M. pneumoniae infection was present in almost half of the CAP population in east China, with some distinct clinical and radiographic features. Moxifloxacin was an effective antibiotic for this infection.
authors.affiliation: The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. sangxao0707@163.com.
authors.forename: Zongxiao
authors.initials: Z
authors.lastname: Shangguan
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Sun
authors.forename: Minghua
authors.initials: M
authors.lastname: Zhang
authors.forename: Jiguang
authors.initials: J
authors.lastname: Ding
authors.forename: Lingao
authors.initials: L
authors.lastname: Yi
authors.forename: Yuantong
authors.initials: Y
authors.lastname: Gao
authors.forename: Aixia
authors.initials: A
authors.lastname: Zhan
authors.forename: Renguo
authors.initials: R
authors.lastname: Zhao
authors.forename: Xiao
authors.initials: X
authors.lastname: Ci
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D002681:China / Q000453:epidemiology; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009177:Mycoplasma pneumoniae / Q000302:isolation & purification*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology; D015995:Prevalence; D011859:Radiography; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D024841:Fluoroquinolones; D000077266:Moxifloxacin